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Evaluation of rubella, Toxoplasma gondii, and cytomegalovirus
seroprevalences among pregnant women in Denizli province
Aysun KARABULUT1, Yusuf POLAT2, Meral TÜRK3, Yasemin IŞIK BALCI4

Aim: There is no national screening program for rubella, Toxoplasma gondii, and cytomegalovirus (CMV) infections
for pregnant women in Turkey. The purpose of this study was to determine the prevalence of these infections among
pregnant women in Denizli province, and to review seroprevalences reported from different regions of Turkey.
Materials and methods: Between April 2008 and April 2009, 1268 women were investigated for rubella, 1102 for
toxoplasma, and 1000 women for CMV seroprevalences in the first trimester of pregnancy. Toxoplasma and rubella IgM
and IgG antibodies were assayed by the automated Vitros ECiQ system based on an immunometric technique.
Cytomegalovirus IgM and G antibodies were tested using the Chorus enzyme immune assay. We also reviewed the
relevant literature reporting seroprevalences from different regions of Turkey.
Results: Rubella IgG seropositivity was found in 1206 patients (95.1%) with no IgM seropositivity. CMV IgG and IgM
positivities were detected in 987 (98.7%) and 12 (1.2%) subjects, respectively. Of 1102 women evaluated for toxoplasmosis,
408 (37%) were positive for IgG and 15 (1.4%) were positive for IgM. The review of the relevant literature reported from
Turkey showed seroprevalence rates in the range of 92.6%-97.3% for rubella, 93.5%-96.1% for CMV, and 30.7%-69.5%
for toxoplasma.
Conclusion: High seropositivity rates for rubella and CMV in Turkey indicate that most of the women were exposed to
these viruses before child-bearing age. Although rubella and CMV seroprevalences show a relatively homogeneous
distribution throughout Turkey, toxoplasma prevalence varies greatly according to the geographic region.
Key words: Pregnancy, rubella, cytomegalovirus, Toxoplasma gondii, seroprevalence

Denizli bölgesinde gebe kadınlarda rubella, Toxoplasma gondii ve sitomegalovirus
seroprevalansının değerlendirilmesi
Amaç: Türkiye’de gebe kadınlarda rubella, Toxoplasma gondii ve sitomegalovirus (CMV) enfeksiyonları için, ulusal bir
tarama programı yoktur. Bu çalışmanın amacı, bölgemizde gebe kadınlarda rubella, Toxoplasma gondii ve CMV
seroprevalansını belirlemek ve ülkemizin farklı bölgelerinden seroprevalans değerlerini bildiren ilgili literatürü gözden
geçirmektir.
Yöntem ve gereç: Nisan 2008 ve Nisan 2009 tarihleri arasında, gebeliğin ilk trimesterindeki 1268 kadın rubella, 1102
kadın toxoplasma, 1000 kadın da CMV seroprevalansı açısından incelendi. Toxoplasma ve rubella IgM ve IgG antikorları
immünometrik tekniğe dayalı otomatik Vitros ECiQ sistemi ile, CMV IgM ve IgG antikorları ise Chorus enzim
immünoassay yöntemi ile değerlendirildi. Türkiye’nin farklı bölgelerinden seroprevalans değerlerini bildiren ilgili literatür
gözden geçirildi.
Bulgular: Bin-ikiyüz-altı (% 95,1) kadında rubella IgG pozitif saptanırken hiçbir kadında IgM pozitifliği saptanmadı.
CMV IgG ve IgM pozitifliği sırasıyla 987 (% 98,7) ve 12 (% 1,2) hastada saptandı. Toksoplazma için incelenen 1102
kadından, 408’inde (% 37) toksoplazma IgG, 15’inde (% 1,4) toksoplazma IgM pozitifti. Türkiye’den bildirilen literatür
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gözden geçirildiğinde rubella seropozitifliğinin % 92,6 - 97,3 arasında, CMV seropozitifliğinin %93,5 - 96,1 arasında ve
toxoplasma seropozitifliğinin % 30,7 - 69,5 arasında değiştiği gözlendi.
Sonuç: Türkiye’deki yüksek rubella ve CMV seropozitifliği, kadınların çoğunun doğurganlık yaşından önce bu virüslere
maruz kaldığını göstermektedir. Rubella ve CMV seroprevalansı rölatif olarak homojen bir dağılım gösterirken,
toxoplasma seroprevalansı bölgesel farklılıklar göstermektedir.
Anahtar sözcükler: Gebelik, rubella, sitomegalovirus, Toxoplasma gondii, seroprevalans

Introduction
Prenatal infections are thought to be responsible
from 2%-3% of all congenital anomalies (1). Primary
infections caused by Toxoplasma gondii, rubella, and
cytomegalovirus (CMV) in pregnancy can bring
about serious problems in the developing fetus.
Rubella is a viral infection with a tiny red skin rash
and usually affects children. However, when the
primary infection occurs in the first trimester of
pregnancy, the virus may cause congenital rubella
syndrome (CRS) associated with multiple
developmental anomalies (2,3). It is difficult to decide
about rubella seropositivity by means of the patient’s
history because many illnesses with rashes may
simulate rubella and up to 50% of rubella infections
may pass without any symptom (3,4). Therefore,
serologic testing is necessary for detection of
susceptible patients.
Cytomegalovirus (CMV) may affect 0.5% to 1.0%
of all live births (5). It is the most frequent cause of
congenital viral infections and may lead to
sensorineural deafness and mental retardation (5,6).
Intrauterine transmission of CMV occurs as a result of
maternal infection. However, unlike rubella and
toxoplasmosis, fetal infection can occur following
both primary and recurrent infection (reactivation of
endogenous virus or reinfection with a new strain).
Transmission rate varies between 30% and 40% after
primary and 1% following secondary infection (7,8).
The time of infection during pregnancy is also
important in the transmission rate; it is lowest at the
time of conception, the same in the second and first
trimester, and highest in the third trimester (9).
Furthermore, 5% to 10% of infected newborns are
symptomatic at birth and among asymptomatic
newborns 10% to 15% will eventually show some
developmental disorders, mainly sensorineuralhearing loss (10).
160

Toxoplasma gondii is an obligate intracellular
protozoan with worldwide distribution influencing
both animals and humans (11). Sexual forms of the
parasite are found in the intestinal epithelium of
definitive hosts such as domestic cats where they
transform into oocysts subsequently shed into the
environment. Oocysts are transmitted to other hosts
through ingestion of undercooked meat or contact
with feline feces or from soil (12). In
immunocompetent humans, 90% of T. gondii
infections are asymptomatic, or may mimic a minor
viral illness (13). Nevertheless, primary infection
during pregnancy may cause spontaneous abortion,
major ocular and neurological problems, or stillbirth
depending on the virulence of the parasite, the
immune response of the mother, and stage of the
pregnancy (14). Effective prevention of congenital
disease depends on avoidance of infection during
pregnancy (15). Due to its long-term complications
and the fact that T. gondii is omnipresent,
epidemiological studies on its seroprevalence help to
shape health policies in individual countries.
The aims of this study were to assess the
seroprevalence of rubella, Toxoplasma gondii, and
CMV infections through antenatal screening in
Denizli province, and compare our findings with
those reported in other studies from Turkey. We
assume that the results of this study would provide
further information to estimate the susceptibility of
pregnant women to congenital infections, and enforce
appropriate preventive measures.
Materials and methods
Study population
The study subjects were recruited from pregnant
women undergoing routine obstetrical evaluation
between April 2008 and April 2009 in Denizli State
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Hospital, Denizli, Turkey. A total of 1268 women with
a mean age of 28.2 years (range 18-40 years) were
tested for rubella seroprevalence, 1102 women with a
mean age of 29.8 years (range, 18-40 years) were
evaluated for Toxoplasma gondii seropositivity, and
1000 women with a mean age of 29.4 years (range, 1840 years) were screened for CMV seroprevalence in
the first trimester of pregnancy. The study protocol
was approved by the local research ethics committee
and informed consent was obtained from all
participants.
Serology
Peripheral blood samples were obtained from
pregnant patients in the first trimester for laboratory
tests. Toxoplasma and rubella IgM and IgG antibodies
were assayed by the automated Vitros ECiQ system
based on an immunometric technique (Vitrous
ECIQB system Johnson & Johnson, New Brunswick,
NJ, USA). Cytomegalovirus IgM and G antibodies
were tested using the Chorus enzyme immune assay
(Chorus Elisa system, Disease Diag., Siena, Italy). The
assays were performed according to the
manufacturer’s instructions. CMV IgM antibody titers
greater than 1.1 ratio and CMV IgG antibody titers
greater than 1.2 IU/mL were regarded as positive.
Rubella IgG antibody titers above 10.0 ratio and IgM
titers above 1.0 ratio were considered positive.
Toxoplasma IgG antibody titers greater than 3.0
IU/mL and IgM greater than 1.0 ratio were considered
positive. All positive results were double-checked. We

also reviewed the relevant literature reporting
seroprevalences from different regions of Turkey.
Results
Rubella IgG seropositivity was detected in 1206
(95.1%) of 1268 subjects with no patient with IgM
seropositivity. CMV IgG and IgM seroprevalences
were detected in 987 (98.7%) and 12 (1.2%) of 1000
pregnant individuals, respectively.
Of the 1102 women evaluated for toxoplasmosis,
408 (37%) were positive for toxoplasma IgG, and 15
(1.4%) were positive for IgM. The rates of
seropositivity for rubella, CMV and toxoplasma were
shown on Table 1.
Four of 12 patients with IgM seropositivity for
CMV and 9 of 15 patients with IgM seropositivity for
toxoplasma showed high avidity. These patients had
uneventful perinatal follow up and healthy babies. On
the other hand, 8 patients with IgM seropositivity for
CMV and 6 patients with IgM seropositivity for
toxoplasma showed low avidity, and they were
referred to institutions with well-equipped
perinatology units.
The review of the pertinent literature reported
from Turkey showed a 95.9% (range 92.6%-98.7%)
seroprevalence rate for rubella, 94.9% (range 93.5%96.1%) seropositivity for CMV, and 47.2% (range
30.7%-69.5%) seroprevalence rate for toxoplasma
(Table 2).

Table 1. The rates of seropositivity for rubella Toxoplasma gondii and cytomegalovirus
(CMV) infections.
Test

Negative (n)

%

Positive (n)

%

Total

Anti-Rubella IgM

1268

100

0

0

1268

Anti-Rubella IgG

62

4.9

1206

95.1

1268

Anti-Toxoplasma IgM

1087

98.6

15

1.4

1102

Anti-Toxoplasma IgG

694

63

408

37

1102

Anti-CMV IgG

13

1.3

987

98.7

1000

Anti-CMV IgM

988

98.8

12

1.2

1000
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Table 2. Comparison of studies evaluating rubella, toxoplasma, and CMV seroprevalences from different regions
of Turkey.
Study

District
seropositivity (%)

Rubella
seropositivity (%)

Toxoplasma
seropositivity (%)

CMV

Present study

Denizli

95.1%

37%

98.7%

Kaleli et al. (23)

Denizli

93.5%

-

93.1%

Aksakal et al. (19)

Ankara

94.5%

-

-

Yılmazer et al. (20)

Afyon

95.1%

30.7%

92.6%

Uyar et al. (21)

Samsun

94.3%

-

97.3%

Tamer et al. (22)

Kocaeli

96.1%

-

96.4%

Ocak et al. (29)

Hatay

95.5%

52.1%

97.3%

Harma et al. (30)

Urfa

-

60.4%

-

Tekay et al. (27)

Urfa

-

69.5%

-

Kayseri

-

33.4%

-

İnci et al. (31)

Discussion
Toxoplasma, rubella, and CMV are important
microbiological agents causing perinatal infections.
These infections often lead to mild or asymptomatic
infection in the mother. However, they may result in
serious congenital abnormalities, intra-uterine growth
retardation, and even death of the fetus (16-18).
Rubella is an important agent for the first trimester
maternal infections. In Turkey, rubella vaccine was
incorporated into the national immunization
program in 2006. However, no vaccination program is
available for rubella after the age of 18. Previous
studies from different regions of Turkey reported high
rubella seropositivity ranging between 93.5% and
96.1% in first trimester pregnancies (Table 2) (19-23).
Concordantly, rubella IgG positivity was found as
93.5% in a previous study conducted in 302 pregnant
patients in Denizli (23). The seroprevalence rate of
95.1% in our study indicates a small increase, which
was probably due to the rubella vaccination program
that commenced in 2006 for subjects under 18 years
old. However, because we did not obtain data with
respect to rubella vaccination status in our study, the
degree of influence of the vaccination program cannot
be determined definitively. Since the susceptibility of
pregnant women to rubella was found to be low in our
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study, the necessity of rubella vaccination in the childbearing age group remains controversial. Larger
studies from different age groups from urban and
rural settings are needed to determine the necessity
of such a national vaccination program for this
country.
The high rate of seropositivity detected in this
study was also similar to the rates reported in different
countries without national vaccination programs in
adults. Rubella seroprevalence was reported to be
96.2% in Iran (24), 91.1% in Saudi Arabia (25), and
92.2% in Egypt (26), among non-vaccinated women
of reproductive age.
Our results showed that toxoplasma IgM and IgG
seropositivities in pregnant women were 1.4% and
37% respectively. There was no patient with both
toxoplasma IgM and IgG seropositivity. Toxoplasma
gondii prevalence is higher in places consuming
undercooked meat. In Turkey, the seroprevalence of
Toxoplasma gondii varies greatly among different
regions ranging from 30.7% to 69.5% (Table 2). The
seroprevalence is higher in eastern and central
Anatolia probably due to consumption of
undercooked meat and raw vegetables (20,27-31).The
increased number of stray cats especially in the rural
regions may also contribute to the high rates.
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Toxoplasma seropositivity was reported as 43.8% in
France (32), and 62.8% in Brazil (33). Lower
seroprevalence rates were reported in the United
Kingdom (34) and Norway (14) (7.7%-9.1% and
10.9% respectively). The likelihood of acquiring
primary toxoplasma infection during pregnancy is
high in subjects without previous exposure to
infection, particularly for those migrating to areas
with higher rates of seroprevalence. As a result, it is
important to detect seronegative pregnant women and
educate them about simple protective measures such
as hand washing, flushing all vegetables and fruits,
and avoidance of raw or undercooked meat
consumption.
In our study, the seropositivity rate of pregnant
women for CMV IgM and IgG antibodies were 1.2%
and 98.7% respectively. Previous studies from
different locations of Turkey showed CMV
seroprevalence rate in the range of 92.6%-97.3%
(Table 2) (20,21,23). The rate was reported to be
46.8% in France (35), 56.3% in Finland (36), 78% in
Russia (37), 84% in Spain (38), and 92.1% Saudi
Arabia (39). CMV infections are highly associated
with poor hygienic conditions, communal life style,
and close contact with day care units (35). Therefore,
hygiene information has a positive impact and could
significantly reduce the incidence of maternal CMV
infection during pregnancy for seronegative patients
(24). Whether the CMV testing has to be proposed to
all pregnant women or restricted to high risk
populations is still under debate in the scientific
community.

Our study has a few limitations. First, we
investigated the seroprevalences only in the first
trimester of pregnancy. Because we did not have
longitudinal follow up in all patients during the later
stages of pregnancy, we do not have the data regarding
the outcome of pregnancy and the well-being of the
newborns. It would have been valuable to provide
information whether or not the pregnant women
without immunity to rubella or toxoplasma acquired
infections. Second, we did not obtain information
about the rubella vaccination status of pregnant
women. Because all women under the age of 18 have
been vaccinated since July 2006, we can assume that
women under the age of 21 have probably been
vaccinated previously. Third, we also did not collect
information about the living conditions, eating habits,
or socioeconomic and educational status, which could
have been more explanatory for toxoplasma and
CMV seropositivity rates.
In conclusion, results for rubella and CMV
seropositivity in Denizli district were similar to those
of other regions of Turkey. However, seroprevalence
for Toxoplasma gondii was lower compared to other
regions. Although most of the women were exposed
to rubella and CMV before child-bearing age in our
district, the significant population was susceptible to
Toxoplasma gondii. The necessity of a rubella
vaccination program in adults is a subject of debate in
this country due to the high rate of rubella
seropositivity. The education of pregnant women
about transmission routes and measures seems to be
the only effective way to protect seronegative women
from toxoplasma and CMV infections.
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